📑 Extensive Product Profile: Carzomib 60 mg Injection
Carzomib 60mg Injection is an advanced, specialized antineoplastic therapeutic formulated for systemic oncology care. Developed as a second-generation targeted intervention, it selectively disrupts complex cellular pathways in specific malignancies. Distributed globally to fulfill specialized hospital procurement requirements, international clinical tenders, and clinical setups, it is prescribed by oncology specialists worldwide to manage refractory or relapsed hematological conditions.
Dosage Form: Lyophilized powder for solution for intravenous (IV) infusion
Commercial Strength: 60 mg per single-dose vial
Active Ingredient: Carfilzomib (60 mg)
Primary Manufacturer: Hetero Healthcare Limited
1. Clinical Indications & Usage
Carzomib 60mg Injection is an advanced targeted therapy globally indicated for:
Relapsed or Refractory Multiple Myeloma: Deployed as a primary systemic intervention for adult patients with advanced bone marrow plasma cell malignancies who have progressed after receiving one or more prior lines of standard therapy (e.g., bortezomib or immunomodulatory agents).
Combination or Maintenance Regimens: Administered either as a highly potent single agent monotherapy or synergistically in combination with established therapeutic regimens—such as Dexamethasone (
$Kd$), Lenalidomide plus Dexamethasone ( $KRd$), or Daratumumab plus Dexamethasone—to significantly improve progression-free survival rates. Targeted Intervention for Resistant Disease: Specifically indicated when a patient's disease becomes resistant to previous lines of oncology therapy, offering a crucial pathway to overcome chemoresistance.
2. Mechanism of Action: How Carzomib Works
Carzomib functions through a highly selective and precise biomolecular pathway engineered to halt malignancy progression:
Targeted Intracellular Inhibition: The active therapeutic structural compound in Carzomib, Carfilzomib, is a selective and irreversible proteasome inhibitor.
It targets the 26S proteasome complex within cells. Disruption of Cellular Signaling: It binds permanently to the N-terminal threonine-containing active sites of the 20S proteasome (the proteolytic core within the 26S complex).
This prevents the targeted breakdown of ubiquitinated proteins, severely disrupting multiple downstream signaling pathways within the cell. Induction of Programmed Apoptosis: Because malignant plasma cells produce massive amounts of abnormal proteins, blocking their clearance triggers a severe intracellular buildup.
This leads to profound endoplasmic reticulum (ER) stress, downregulates the NF-κB pathway (which normally promotes cell survival and chemoresistance), and drives the cancer cells into programmed cell death (apoptosis) while sparing most non-cancerous tissues.
3. Administration and Dosing Guide
Administration Route: Carzomib is formulated as a sterile 60 mg lyophilized cake/powder in a single-dose vial.
It is administered exclusively via Intravenous (IV) Infusion. It must never be given as an automated IV push, unmonitored bolus, or via any other route. Infusion Schedule: Carzomib is typically administered in 28-day treatment cycles.
The standard protocol includes delivering the IV infusion on 2 consecutive days each week for 3 consecutive weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Infusion Duration & Premedication: Depending on the specific protocol and dosage escalation framework, the infusion is delivered over 10 to 30 minutes.
Premedication with dexamethasone is strongly advised prior to all doses in Cycle 1 to significantly mitigate the incidence and severity of acute infusion-related reactions.
4. Safety, Side Effects, and Monitoring
Carzomib is an exceptionally potent targeted antineoplastic agent requiring specialized oncological observation.
⚠️ Severe Systemic Adverse Reactions: Because Carzomib actively alters intracellular homeostasis, it requires strict monitoring of cardiac, renal, and hematological baselines.
Hematological Fluctuations (Myelosuppression): It can cause severe decreases in blood counts, leading to anemia, neutropenia, and thrombocytopenia (low blood platelets).
Platelet nadirs typically occur around Day 8 of each cycle. Complete Blood Counts (CBC) must be monitored routinely. Cardiovascular Complications: Serious, sometimes fatal, cardiac toxicities including congestive heart failure (CHF), myocardial infarction (MI), and cardiac arrest have been reported.
Close monitoring of blood pressure, fluid management, and pre-existing cardiac conditions is mandatory. Organ System Toxicities: Acute kidney injury and sudden renal failure have occurred; patients must maintain robust, structured hydration before and after dosing.
Routine liver function tests (LFTs) are also essential due to the risk of drug-induced hepatotoxicity. Common Side Effects: Fatigue, generalized physical weakness, pyrexia (fever), nausea, diarrhea, vomiting, shortness of breath (dyspnea), cough, headaches, and upper respiratory tract infections.
5. Storage, Stability & Commercial Packaging
As a premium biological/oncological therapeutic, Carzomib requires strict compliance with cold-chain protocols and precise handling from manufacturing through to international delivery.
Cold-Chain Storage Framework: Store Carzomib 60 mg vials under strict, uninterrupted refrigeration continuously between 2°C to 8°C (36°F to 46°F).
Environmental Safeguards: Keep the single-dose vials inside their original manufacturer carton to protect the lyophilized formulation from direct light and UV exposure. Do not freeze, and do not shake the vials. Freezing irreversibly denatures the active structure, while mechanical agitation can cause protein aggregation.
Dilution & Stability Protocol: Reconstitute and dilute only with recommended fluids (such as 5% Dextrose Injection or 0.9% Sodium Chloride) under strict aseptic conditions. Because the formulation contains no antimicrobial preservatives, the diluted solution should be administered promptly.
Indian Export & Bulk Supply Excellence: Ernest Impex acts as a secure international conduit by managing temperature-controlled logistics for bulk pharmaceutical exports. Utilizing certified passive and active cold-chain shipping structures, calibrated thermal insulators, and real-time electronic data loggers, we guarantee that Carzomib 60mg Injection arrives at international clinical destinations with its biological stability, structural integrity, and clinical efficacy completely intact.
6. Regulatory and Compliance Documentation
ERNEST IMPEX provides an audit-ready compliance framework to facilitate smooth customs and international clinical supply verification:
Authentic Certificate of Analysis (COA) per batch production
Validated Cold-Chain Transport Log and Origin Ledger
Global Import/Export Regulatory Compliance Papers
💡 Why Choose ERNEST IMPEX?
Procuring oncology supplies through ERNEST IMPEX ensures uncompromised logistical reliability:
Validated Cold-Chain Integrity: Continuous temperature monitoring from storage vaults to destination delivery ports.
Clear Supply Traceability: Direct sourcing infrastructure ensuring valid batch verification from India.
Logistical Security: Experienced distribution patterns minimizing import clearance delays for specialized biologics.
PRESCRIPTION MEDICINE IS : YES
Clinical Disclaimer : This profile is compiled strictly for international wholesale procurement and commercial educational research. Carzomib 60 mg Injection is a specialized oncology drug available exclusively under clinical authorization (PRESCRIPTION MEDICINE IS YES).
It must be handled, dispensed, and utilized solely under the direct guidance of a registered oncology specialist. Carzomib is unsafe for use during pregnancy due to positive evidence of embryo-fetal harm or toxicity based on animal data. Effective non-hormonal contraception must be implemented by patients during treatment and for a mandatory period post-final dose. Breastfeeding is strictly contraindicated during treatment due to severe potential toxicity to the infant. All cross-border importing processes must comply with the native regulatory frameworks of the destination country.
📞 Contact Ernest Impex — Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
📲 WhatsApp Link:
